8-K filing — HERON THERAPEUTICS, INC. /DE/ (HRTX)
Filed: 2026-09-29 AccNo: 0001193125-26-407728 Size: 198 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Heron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License Agreement
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Downgrades Heron Therapeutics to Neutral
HC Wainwright & Co. analyst Brandon Folkes downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Neutral.
Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.